Each year since 2007, G-FINDER has provided policy-makers, donors, researchers and industry with a comprehensive analysis of global investment into research and development of new products to prevent, diagnose, control or cure neglected diseases in developing countries, making it the gold standard in tracking and reporting global funding for neglected disease R&D. This year’s report, the thirteenth overall, focuses on investments made in participants’ 2019 financial year.
Hepatitis B was included in 2019 following advocacy from ICE-HBV. While the report shows an increase in investments, the gap between the impact of the virus on public health and investments being made is still striking.
Read the 2020 report here.